201 related articles for article (PubMed ID: 24678059)
1. Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.
Mahal K; Resch M; Ficner R; Schobert R; Biersack B; Mueller T
ChemMedChem; 2014 Apr; 9(4):847-54. PubMed ID: 24678059
[TBL] [Abstract][Full Text] [Related]
2. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
5. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
[TBL] [Abstract][Full Text] [Related]
6. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors.
Mahal K; Biersack B; Schruefer S; Resch M; Ficner R; Schobert R; Mueller T
Eur J Med Chem; 2016 Aug; 118():9-20. PubMed ID: 27116710
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.
Rickardson L; Kutvonen E; Orasniemi S; Högberg M; Kallio MJ; Rehnmark S
Drug Des Devel Ther; 2017; 11():1335-1351. PubMed ID: 28496304
[TBL] [Abstract][Full Text] [Related]
9. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
Schobert R; Biersack B; Dietrich A; Effenberger K; Knauer S; Mueller T
J Med Chem; 2010 Sep; 53(18):6595-602. PubMed ID: 20731355
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
Wang G; Li C; He L; Lei K; Wang F; Pu Y; Yang Z; Cao D; Ma L; Chen J; Sang Y; Liang X; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2014 Apr; 22(7):2060-79. PubMed ID: 24629450
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiproliferative activity of 4-substituted-piperazine-1-carbodithioate derivatives of 2,4-diaminoquinazoline.
Cao SL; Han Y; Yuan CZ; Wang Y; Xiahou ZK; Liao J; Gao RT; Mao BB; Zhao BL; Li ZF; Xu X
Eur J Med Chem; 2013 Jun; 64():401-9. PubMed ID: 23665106
[TBL] [Abstract][Full Text] [Related]
12. Quinazoline-sulfonamides as potential antitumor agents: synthesis and biological testing.
Alafeefy AM; Alqasoumi SI; Ashour AE; Alshebly MM
J Enzyme Inhib Med Chem; 2013 Apr; 28(2):375-83. PubMed ID: 22468752
[TBL] [Abstract][Full Text] [Related]
13. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
[TBL] [Abstract][Full Text] [Related]
15. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
16. Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity.
Deng ZT; Feng T; Wang P; Qi X; Chen XH; Li YX; Song CL; Geng MY; Li J
Biochem Pharmacol; 2011 Dec; 82(12):1832-42. PubMed ID: 21920350
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents.
Devegowda PS; Balaji KS; Prasanna DS; Swaroop TR; Kameshwar VH; Jayarama S; Siddalingaiah L; Rangappa KS
Anticancer Agents Med Chem; 2018 Feb; 17(14):1931-1941. PubMed ID: 28403784
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, in vitro and in vivo evaluation of novel substituted N-(4-(2-(4-benzylpiperazin-1-yl)ethoxy)phenyl)-N-methyl-quinazolin-4-amines as potent antitumor agents.
Cao D; Wang X; Lei L; Ma L; Wang F; Wang C; Tang M; Xiang W; Wang T; Li H; Chen L
Bioorg Med Chem Lett; 2016 Apr; 26(8):1931-5. PubMed ID: 26979159
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of 2-mercapto-3-phenethylquinazoline bearing anilide fragments as potential antitumor agents: molecular docking study.
Al-Suwaidan IA; Alanazi AM; Abdel-Aziz AA; Mohamed MA; El-Azab AS
Bioorg Med Chem Lett; 2013 Jul; 23(13):3935-41. PubMed ID: 23683592
[TBL] [Abstract][Full Text] [Related]
20. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
